MedTrace Logo

Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis

NCT05167760 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.

Conditions

  • Synkinesis
  • Facial Nerve Palsy

Interventions

DRUG

Apraclonidine

1-2 drops per eye every 8 hours for 2 weeks

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Benjamin Greene, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2027-11-30
Completion
2028-11-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167760 on ClinicalTrials.gov